Loading...
Immunotherapy (pembrolizumab) is FDA-approved for use with chemotherapy, with or without bevacizumab, in the frontline setting for patients with metastatic or recurrent cervical cancer with programmed cell death ligand 1 (PD-L1) tumor expression (combined positive score [CPS] ≥1). In the current study, investigators evaluated the PD-L1 inhibitor atezolizumab in combination with platinum-based chemotherapy and mandatory bevacizumab in patients with metastatic or recurrent cervical cancer, regardless of PD-L1 tumor expression. In the industry-funded, multinational, open-label, phase 3 trial, 410 patients were randomized to standard therapy (cisplatin or carboplatin, paclitaxel, and bevacizumab) either with or without the addition of atezolizu…